Drug intelligence / Profile preview

pivampicillin

Development stage
Unknown
Lead developer
LEO Pharma
Modality
Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

Pivampicillin is a semisynthetic, orally active pivaloyloxymethyl ester of ampicillin and serves as a prodrug to enhance the oral bioavailability of ampicillin due to its increased lipophilicity. After oral administration, it is rapidly hydrolyzed by non-specific esterases in the body to release active ampicillin along with formaldehyde and pivalic acid. Ampicillin exerts its antibacterial effect by binding to and inactivating penicillin-binding proteins (PBPs) on the bacterial cell wall's inner membrane. This action inhibits peptidoglycan cross-linking necessary for cell wall strength and rigidity, leading to bacterial cell lysis. Pivampicillin is primarily indicated for treating susceptible bacterial infections such as gonococcal urethritis and other infections responsive to ampicillin[1][2][3][5][6].

Brand names
PondocillinMiraxid
Other names
pivaloylampicillinpivampicilinapivampicilline33817-20-8
02

Targets

PBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on pivampicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pivampicillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call